InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.00%
)
US TECH 100
19,214.80
(
0.00%
)
Dow Jones
39,127.80
(
0.00%
)
Brent Oil
85.24
(
0.91%
)
Bitcoin
61,662.82
(
1.40%
)
Post# of 252396
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 67383

Tuesday, 10/14/2008 1:22:53 AM

Tuesday, October 14, 2008 1:22:53 AM

Post# of 252396
Today was a busy news day for ABT. In addition to announcing a $5B share buyback, ABT released data at the TCT conference on Xience and the bioabsorbable stent in development.

In head-to-head studies, Xience bested BSX’s Taxus on both MACE and TLR at two years:
http://biz.yahoo.com/prnews/081013/aqm519.html

ABT’s bioabsorbable stent demonstrated decent results and confirmed bioabsorption in a pilot single-arm study with 30 patients:
http://biz.yahoo.com/prnews/081013/aqm521.html

I think it’s fair to say that ABT is now generally perceived to be the technology leader in the field of drug-eluting stents.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up